The Progress and Development Prospects of Targeted Therapy for Pancreatic Carcinoma

Jingqi Zheng

doi:10.54097/zw3h9980

Authors

Jingqi Zheng

DOI:

https://doi.org/10.54097/zw3h9980

Keywords:

Targeted therapy for pancreatic cancer; EGFR; CAR-T; GRPR.

Abstract

Pancreatic cancer is a malignant tumor with extremely high malignancy and poor prognosis. At present, targeted therapy is the latest progress in the treatment of pancreatic cancer; The development of receptors for drugs targeting pancreatic cancer has also made great progress, and specific drugs targeting some receptors have also been approved for marketing. However, the clinical effect of targeted therapy for pancreatic cancer has not reached a stable state, and the side effects of some targeted drugs have not been effectively solved. This article reviews the research on therapeutic targets for pancreatic cancer such as TROP2, PI3K and CIP2A in recent years and the development of Claudin 18.2, a new target. It is found that the research on Trop2 and CAPA is relatively complete and has achieved effective results. Both of them are effective targets for targeted treatment of pancreatic cancer. However, the research on PI3K and Claudin 18.2 is less, and their effects and mechanisms are not effectively supported by theory. In addition, this article summarized the research on EGFR, Her, CAR-T, GRPR and other receptors related to targeted treatment of pancreatic cancer and their related drugs and therapies. It was found that the research on EGFR, Her and CAR-T had achieved significant research results in the clinical stage, and their related drugs and therapies were approved for marketing; However, there are still deficiencies in the research on the influencing factors, stable clinical efficacy, and side effects of drugs targeting the aforementioned receptors. Future research can focus on overcoming tumor microenvironment, avoiding side effects of targeted drugs for pancreatic cancer, and new targets for targeted treatment of pancreatic cancer.

Downloads

Download data is not yet available.

References

Ding L, and Zhang P. "Advances in the treatment of pancreatic cancer." Chinese Journal of Gerontology. 2014, 8:3.

Shi Y M, et al. "Advances in targeted therapeutic drugs for pancreatic cancer." Pharmaceutial Care & Research, vol. 19, no. 4, 2019, pp. 241-320. The EBSCOhost

Zhang Feiyu, et al. "New advances in targeted tumor microenvironment therapy for pancreatic cancer." Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi, vol. 37, no. 9, Sept. 2021, pp. 2246–48.

Xu M. "Mechanism and targeted therapy of pancreatic cancer microenvironment." Journal of Clinical Hepatology / Linchuang Gandanbing Zazhi, vol. 38, no. 4, Apr. 2022, pp. 965–68.

Cancer Encyclopedia. "Pancreatic cancer patients must read! These targets must be detected before receiving targeted therapy". Health Community. 2021.

Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer, 2010, 9: 253.

Qiu J R, Tang Q, Lin H, et al. Expression and clinical significance of Trop-2 in human pancreatic cancer. Natl Med J China, 2011, 91(2): 103-106.

Zhou T, Zhang Y P, Zhang Q W. Effect of targeted inhibition of TROP2 gene expression on the biological characteristics of pancreatic cancer cells. Oncol Prog, 2018, 16(3): 290-294.

Song W, Guiping Y, Tao X. Recent progress in anti-tumor studies of inhibitors of PI3K-mTOR signaling pathway. China Medical Review, 2015, (1): 161-164.

Tongjun Z, Dong X, Xinjun L, et al. Expression of CIP2A, PI3K and Survivin in pancreatic cancer and their clinical significance. Chinese Journal of Medical Doctors, 2015, (2):198-201.

Jian-shi C, Zhi-qiang Z. Expression of protein phosphatase 2A cancerous inhibitor (CIP2A) in gastric cancer and its clinical significance. The one they called bean network. 2012.

Jingdong F, Dong X, Chang Gang, et al. Expression of CIP2A, p-Akt, N-cadherin and MMP-9 in pancreatic cancer and its clinical significance. Advances in modern Chinese general surgery.2014, (10):779-783.

Tongjun Z, Dong X, Xinjun L, et al. Expression of CIP2A, PI3K and Survivin in pancreatic cancer and their clinical significance. Chinese Journal of Medical Medicine.2015, (2):198-201.

Global oncologists. Claudin18.2 (CLDN18.2) targets positive rate of over 50%, CLDN18.2 targeted drug for pancreatic cancer targeted therapy brings new hope. 2023.

Qi C S, Gong J F, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med, 2022, 28(6): 1189-1198.

Global oncologists. Claudin18.2 (CLDN18.2) targets positive rate of over 50%, CLDN18.2 targeted drug for pancreatic cancer targeted therapy brings new hope. 2023.

Cheng Z, Jian Z. Leading research progress and prospect of antibody-drug conjugate in pancreatic cancer in 2022. China Oncology, 2023, 33(3): 235-240.

Hynes N, Lane H. Erbb receptor and cancer: the complexity of targeted inhibitor. Nat Rev Cancer, 2005, 5(5):341-355.

Eser S, Schnieke A, Schneider G, et al. Oncogenic KRAS signalingin pancreatic cancer. Br J Cancer, 2014, 111 (5): 817-822.

Wei G, Yu H. Pancreatic cancer molecular targeted therapy progress. Cancer, 2018, 38 (2): 7.

Changshan H, Wei Y, Qian W, Yuechao D, et al. Targeting of anti-human epidermal growth factor receptor 2/ epidermal growth factor receptor bispecific antibody against human pancreatic cancer cells PANC-1. Chinese Journal of Experimental Surgery,2017,34(8):1330-1332

Pan Z Y, Zhan X B. Current status and future strategy of chimeric antigen receptor T cells in the treatment of pancreatic cancer. Chinese Journal of Cancer, 2019, 29(7): 481-485.

Xuan R, Ling G, Changlin Z, et al. Gastrin-releasing peptide receptors are involved in tumor progress and research progress of targeted treatment. Journal of biotechnology drugs, 2019, 26 (3): 265-268.T